Literature DB >> 21613811

Clinical presentations of thyroid cancer patients with multiple primary cancers.

J D Lin1, K J Lin, T C Chao, C Hseuh, N M Tsang, B Y Huang.   

Abstract

BACKGROUND: In thyroid cancer patients with multiple primary cancers, primary cancers tend to be more aggressive. AIMS: We analyzed multiple primary cancers in thyroid cancer patients and determined the differences between the incidence and the characteristics of primary cancers.
MATERIALS AND METHODS: A total of 3070 patients with thyroid cancer underwent a thyroidectomy and follow-up examination at a single medical center. The times of diagnosis of the primary cancers were categorized as antecedent, synchronous, or subsequent to the diagnosis of thyroid cancer.
RESULTS: After a mean follow-up period of 8.8 ± 0.5 yr, the presence of multiple primary cancers was histopathologically confirmed in 163 patients (5.3%). Patients with multiple primary cancers had a lower female-to-male ratio, an older mean age, advanced tumor-node-metastasis (TNM) stage, higher total mortality, and higher therapeutic radioactive iodide (131I) doses than patients without multiple primary cancers. Hematological malignancy and renal cell carcinoma, neither of which are among the 10 most common cancers observed in the general population of Taiwan, were the most common multiple cancers among women and men with thyroid cancer. Patient age, thyroid cancer tumor size, and thyroid cancer mortality in the antecedent, synchronous, and subsequent groups were not significantly different.
CONCLUSIONS: Patients with multiple primary cancers in advanced stages had shorter disease-free survival period after treatment. Thyroid cancer patients with multiple primary cancers should be closely followed up for the occurrence of other secondary cancers in order to improve total mortality.

Entities:  

Mesh:

Year:  2011        PMID: 21613811     DOI: 10.3275/7747

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

2.  Nonbreast second malignancies after treatment of primary breast cancer.

Authors:  Budhi S Yadav; Suresh C Sharma; Firuza D Patel; Sushmita Ghoshal; Rakesh Kapoor; Rajinder Kumar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-19       Impact factor: 7.038

3.  Thyroid cancer and multiple primary tumors in the SEER cancer registries.

Authors:  Cécile M Ronckers; Peter McCarron; Elaine Ron
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

4.  131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study.

Authors:  C Ceccarelli; W Bencivelli; D Morciano; A Pinchera; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

5.  Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer.

Authors:  Raewyn M Seaberg; Spiro Eski; Jeremy L Freeman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-04

6.  Risk of second primary cancer following differentiated thyroid cancer.

Authors:  Emmanuelle Berthe; Michel Henry-Amar; Jean-Jacques Michels; Jean-Pierre Rame; Pascaline Berthet; Emmanuel Babin; Philippe Icard; Guy Samama; Françoise Galateau-Sallé; Jacques Mahoudeau; Stéphane Bardet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-28       Impact factor: 9.236

7.  Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries.

Authors:  Shu-Chun Chuang; Mia Hashibe; Ghislaine Scelo; David H Brewster; Eero Pukkala; Soren Friis; Elizabeth Tracey; Elisabete Weiderpass; Kari Hemminki; Sharon Tamaro; Kee-Seng Chia; Vera Pompe-Kirn; Erich V Kliewer; Jon M Tonita; Carmen Martos; Jon G Jonasson; Carolyn M Dresler; Paolo Boffetta; Paul Brennan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

8.  Leukaemias and cancers following iodine-131 administration for thyroid cancer.

Authors:  F de Vathaire; M Schlumberger; M J Delisle; C Francese; C Challeton; E de la Genardiére; F Meunier; C Parmentier; C Hill; H Sancho-Garnier
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Second malignancies after breast cancer: the impact of different treatment modalities.

Authors:  Y M Kirova; Y De Rycke; L Gambotti; J-Y Pierga; B Asselain; A Fourquet
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

10.  Second primary malignancies in thyroid cancer patients.

Authors:  C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more
  2 in total

1.  Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer.

Authors:  Chung-Huei Huang; Tzu-Chieh Chao; Chuen Hseuh; Kun-Ju Lin; Tsung-Ying Ho; Shu-Fu Lin; Jen-Der Lin
Journal:  Pediatr Surg Int       Date:  2012-01-25       Impact factor: 1.827

2.  Differences Between Cancer-Specific Survival of Patients With Anaplastic and Primary Squamous Cell Thyroid Carcinoma and Factors Influencing Prognosis: A SEER Database Analysis.

Authors:  Shuai Jin; Xiangmei Liu; Dandan Peng; Dahuan Li; Yuan-Nong Ye
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-10       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.